(Total Views: 477)
Posted On: 03/31/2021 1:08:53 PM
Post# of 153986
I wanted to clarify something Dr. Patterson is writing the prescriptions.
Am I wrong wasn’t the choice of the members of the DSMB made by the company?
Can dosing and route of administration be considered a violation of trial design.
If increased doses are proposed for a change in trial design, could the FDA, ask to repeat phase1/2 to determine safety at the higher dosing?
I think a change in the route of administration, which probably would have been granted . Moreover Dr. Patterson’s paper showed onset of action was around 3 days (probably due to poor absorption in critical patients) a lot of time for the study group to have advanced disease. IV would have immediate action.
I have used the example of insulin in the ICU. Translating the out patients HIV experience to the ICU perhaps was not a good idea in trial design. Maybe to keep the mantra that there is an advantage in not having to start an IV??. The average patient in the unit may have 6-8 IV’s in already. I think if an intensivist was involved CD-12 would be different and perhaps be more successful.
Am I wrong wasn’t the choice of the members of the DSMB made by the company?
Can dosing and route of administration be considered a violation of trial design.
If increased doses are proposed for a change in trial design, could the FDA, ask to repeat phase1/2 to determine safety at the higher dosing?
I think a change in the route of administration, which probably would have been granted . Moreover Dr. Patterson’s paper showed onset of action was around 3 days (probably due to poor absorption in critical patients) a lot of time for the study group to have advanced disease. IV would have immediate action.
I have used the example of insulin in the ICU. Translating the out patients HIV experience to the ICU perhaps was not a good idea in trial design. Maybe to keep the mantra that there is an advantage in not having to start an IV??. The average patient in the unit may have 6-8 IV’s in already. I think if an intensivist was involved CD-12 would be different and perhaps be more successful.
(4)
(0)
